Tetryzoline

S01G - Decongestants and antiallergics ATC S01GA52 Small molecule approved 1979 Topical Natural product

JFDA label: Trillerg

Indications

Approved

Eye Manifestations — eye allergy
Nasal Obstruction — Nasal congestion

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Cardiac disorders (1)

Not Known Palpitations

Nervous system disorders (4)

Not Known Dizziness · Headache · Somnolence · Tremor

Skin and subcutaneous tissue disorders (1)

Not Known Erythema

Psychiatric disorders (1)

Not Known Insomnia

Infections and infestations (1)

Not Known Rhinitis

General disorders and administration site conditions (5)

Not Known Asthenia · Pain · Sneezing · Swelling · Sympathomimetic effect

Dosing

Source: openFDA

Directions Directions adults and children 6 years of age and over: put 1 or 2 drops in the affected eye(s) up to 4 times a day children under 6 years of age: consult a doctor children under 2 years of age: do not use

Warnings & Precautions

Source: openFDA

Warnings & Precautions

Warnings For external use only. Ask a doctor before use Ask a doctor before use if you have narrow angle glaucoma. When using this product When using this product pupils may become enlarged temporarily overuse may cause more eye redness remove contact lenses before using replace cap after each use do not use if this solution changes color or becomes cloudy do not touch tip of container to any surface to avoid contamination Stop use and ask a doctor if Stop use and ask a doctor if you feel eye pain redness or irritation of the eye lasts changes in vision occur condition worsens or lasts more than 72 hours If pregnant or breast-feeding If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Chemistry & Properties

Formula	C13H16N2
Molecular weight	200.28 g/mol
IUPAC name	2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
CAS	84-22-0
PubChem CID	5419
InChIKey	`BYJAVTDNIXVSPW-UHFFFAOYSA-N`
logP	2.11 (XLogP 1.8)
Polar surface area	24.39 Å²
H-bond acceptors / donors	2 / 1
Drug-likeness (QED)	0.74
Lipinski violations	0

SMILES

c1ccc2c(c1)CCCC2C1=NCCN1

Biology & Pharmacokinetics

Pharmacokinetics predicted

Bioavailability	10.0%
Half-life	2.15 h
Volume of distribution	3.846 L/kg
Protein binding	39.9%
BBB penetrant	Yes

Enzyme interactions

Enzyme	Role	Detail
CYP1A2	Substrate	—
CYP2C19	Substrate	—
CYP2C9	Substrate	—
CYP2D6	Inhibitor	—
CYP2D6	Substrate	—
CYP3A4	Substrate	—

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)

Registered Products (1)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
Trillerg	Solution 0.4 mg/1 ml, 0.5 mg/1 ml	10 ml	Nabulsi Drug Store	1.560